Novavax Inc
NASDAQ:NVAX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.76
20.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Novavax Inc
Gross Margin
Novavax Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | US |
| Market Cap | 1.4B USD |
| Gross Margin |
64%
|
| Country | FR |
| Market Cap | 6T USD |
| Gross Margin |
0%
|
| Country | US |
| Market Cap | 314.3B USD |
| Gross Margin |
67%
|
| Country | US |
| Market Cap | 142.4B USD |
| Gross Margin |
60%
|
| Country | US |
| Market Cap | 119B USD |
| Gross Margin |
86%
|
| Country | US |
| Market Cap | 112.1B USD |
| Gross Margin |
78%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Gross Margin |
76%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Gross Margin |
52%
|
| Country | US |
| Market Cap | 81.3B USD |
| Gross Margin |
87%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Gross Margin |
75%
|
| Country | NL |
| Market Cap | 34.5B EUR |
| Gross Margin |
89%
|
Novavax Inc
Glance View
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Novavax Inc's most recent financial statements, the company has Gross Margin of 63.8%.
You don't have any saved screeners yet
